Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question

World Journal of Gastroenterology

Volumn 21, Issue 14, 2015, Pages 4103-4110

  Streba, Letitia Adela Maria ^a   Vere, Constantin Cristin ^a   Rogoveanu, Ion ^a   Streba, Costin Teodor ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; Metabolic syndrome; Non alcoholic fatty liver disease; Obesity

Indexed keywords

INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BODY MASS; CELL PROLIFERATION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BLOOD; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DISEASE MODEL; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84927602530     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i14.4103     Document Type: Review

References (96)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 doi: 10.1056/NEJMra011775]
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 doi: 10.1002/hep.25762]
3. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455 [PMID: 10569299]
5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850 [PMID: 11473047 DOI: 10.2337/diabetes.50.8.1844]
6. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 2118-2123 [PMID: 18031368 doi: 10.1111/j.1440-1746.2006.04698.x]
7. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145 [PMID: 16108839 doi: 10.1111/j.1464-5491.2005.01582.x]
8. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303 [PMID: 17295757 DOI: 10.1111/j.1440-1746.2007.04824.x]
9. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013; 19: 3375-3384 [PMID: 23801829 DOI: 10.3748/wjg.v19.i22.3375]
10. Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Nonalcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013; 28: 664-670 [PMID: 23286209 doi: 10.1111/jgh.12106]
11. World Health Organisation (WHO): Overweight and Obesity Factsheet. Available from: URL: http://www.who.int/mediacentre/factsheets/fs311/en/
12. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209 [PMID: 16198769 doi: 10.1016/s0140-6736(05)67483-1]
13. Parsi MA. Obesity and cholangiocarcinoma. World J Gastroenterol 2013; 19: 457-462 [PMID: 23382624 doi: 10.3748/wjg.v19.i4.457]
14. Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev 2008; 32: 190-199 [PMID: 18790577 doi: 10.1016/j.cdp.2008.08.004]
15. Murray L, Romero Y. Role of obesity in Barrett's esophagus and cancer. Surg Oncol Clin N Am 2009; 18: 439-452 [PMID: 19500735 doi: 10.1016/j.soc.2009.03.010]
16. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 285-291 [PMID: 16239255 doi: 10.1136/gut.2005.073163]
17. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007; 86: 556-565 [PMID: 17823417]
18. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies. Lancet 2008; 371: 569-578 [PMID: 18280327 doi: 10.1016/s0140-6736(08)60269-x]
19. Zyromski NJ, White PB. Pancreatic cancer in obesity: epidemiology, clinical observations, and basic mechanisms. Anticancer Agents Med Chem 2011; 11: 470-478 [PMID: 21492072 DOI: 10.2174/187152011795677445]
20. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-155 [PMID: 12085359 doi: 10.1053/jhep.2002.33713]
21. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012; 56: 704-713 [PMID: 22120206 doi: 10.1016/j.jhep.2011.09.020]
22. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223-43, vii-x [PMID: 21689610 doi: 10.1016/j.cld.2011.03.006]
23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 doi: 10.3322/caac.20107]
24. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 doi: 10.1056/nejmra1001683]
25. Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer 2013; 108: 1182-1188 [PMID: 23370206 doi: 10.1038/bjc.2013.25]
26. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842 DOI: 10.1053/gast.2002.34168]
27. Marchesini G, Forlani G, Bugianesi E. Is liver disease a threat to patients with metabolic disorders? Ann Med 2005; 37: 333-346 [PMID: 16179269 doi: 10.1080/07853890510011445]
28. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359.e2 [PMID: 23041539 doi: 10.1016/j.cgh.2012.10.001]
29. World Health Organisation (WHO): Global Database on Body Mass Index. Available from: URL: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html&
30. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32: 1431-1437 [PMID: 18607383 doi: 10.1038/ijo.2008.102]
31. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553 [PMID: 9686693 doi: 10.1002/(SICI)1096-9136(199807)15]
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497 [PMID: 11368702 doi: 10.1001/jama.285.19.2486]
33. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062 [PMID: 16182882 DOI: 10.1016/s0140-6736(05)67402-8]
34. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011; 21: 351-355 [PMID: 21128002 doi: 10.1007/s11695-010-0335-4]
35. Tsigos C, Hainer V, Basdevant A, Finer N, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Yumuk V, Zahorska-Markiewicz B. Criteria for EASO-collaborating centres for obesity management. Obes Facts 2011; 4: 329-333 [PMID: 21921658 doi: 10.1159/000331236]
36. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249-1257 [PMID: 21617109 doi: 10.2337/dc11-0442]
37. Yang WS, Va P, Bray F, Gao S, Gao J, Li HL, Xiang YB. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One 2011; 6: e27326 [PMID: 22205924 DOI: 10.1371/journal.pone.0027326]
38. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832 [PMID: 20432259 doi: 10.1002/hep.23594]
39. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-2271 [PMID: 20458764 doi: 10.3748/wjg.v16.i18.2265]
40. Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20: 9217-9228 [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217]
41. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008 [PMID: 17700568 doi: 10.1002/ijc.23176]
42. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012; 48: 2137-2145 [PMID: 22446023 doi: 10.1016/j.ejca.2012.02.063]
43. Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Sasazuki S, Inoue M, Tsugane S. Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012; 42: 212-221 [PMID: 22241822 doi: 10.1093/jjco/hyr198]
44. Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, Boffetta P, Dahm CC, Overvad K, Tjønneland A, Halkjær J, Fagherazzi G, Boutron-Ruault MC, Carbonnel F, Kaaks R, Lukanova A, Boeing H, Trichopoulou A, Bamia C, Lagiou P, Palli D, Grioni S, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, van den Berg S, Peeters PH, Braaten T, Weiderpass E, Quirós JR, Travier N, Sánchez MJ, Navarro C, Barricarte A, Dorronsoro M, Lindkvist B, Regner S, Werner M, Sund M, Khaw KT, Wareham N, Travis RC, Norat T, Wark PA, Riboli E, Nöthlings U. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013; 132: 645-657 [PMID: 22618881 doi: 10.1002/ijc.27645]
45. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468 [PMID: 14762783 doi: 10.1053/j.gastro.2003.10.065]
46. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702 doi: 10.1016/j.cgh.2005.12.007]
47. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and metaanalysis. Diabetes Metab Res Rev 2012; 28: 109-122 [PMID: 21898753 doi: 10.1002/dmrr.1291]
48. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Populationbased risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191 [PMID: 20666689 DOI: 10.1185/03007995.2010.506375]
49. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443 [PMID: 21128245 doi: 10.1002/ijc.25797]
50. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 doi: 10.1016/j.jhep.2011.10.027]
51. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755 [PMID: 15082596 doi: 10.1136/gut.2003.019984]
52. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100 [PMID: 11438497 doi: 10.1053/gast.2001.25540]
53. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-1766 [PMID: 18976012 DOI: 10.1043/1543-2165-132.11.1761]
54. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-1194 [PMID: 19672551 DOI: 10.1007/s00535-009-0112-0]
55. Rahman RN, Ibdah JA. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: A population based study. Hepatology 2012; 56: 241A
56. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013; 28: 848-854 [PMID: 23302015 doi: 10.1111/jgh.12116]
57. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014; 20: 12945-12955 [PMID: 25278690 doi: 10.3748/wjg.v20.i36.12945]
58. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012; 32: 30-38 [PMID: 22418886 doi: 10.1055/s-0032-1306424]
59. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6: 263-273 [PMID: 24868320 doi: 10.4254/wjh.v6.i5.263]
60. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H, Yoneyama H. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 2013; 46: 141-152 [PMID: 23430399 doi: 10.1007/s00795-013-0016-1]
61. Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hübscher SG, Newsome PN. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014; 184: 1550-1561 [PMID: 24650559 doi: 10.1016/j.ajpath.2014.01.034]
62. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
63. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
64. Streba LA, ɤrstea D, Mitrų P, Vere CC, Dragomir N, Streba CT. Nonalcoholic fatty liver disease and metabolic syndrome: a concise review. Rom J Morphol Embryol 2008; 49: 13-20 [PMID: 18273497]
65. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-1307 [PMID: 20650925 doi: 10.1136/gut.2009.199661]
66. Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15: 281-96, vii-x [PMID: 21689613 doi: 10.1016/j.cld.2011.03.007]
67. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-693 [PMID: 14710347 doi: 10.1055/s-2004-814151]
68. Chun YS, Huang M, Rink L, Von Mehren M. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study. World J Surg Oncol 2014; 12: 231 [PMID: 25052889 doi: 10.1186/1477-7819-12-231]
69. Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011; 4: 30 [PMID: 21729319 doi: 10.1186/1756-8722-4-8730]
70. Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6: 716-737 [PMID: 25349643 doi: 10.4254/wjh.v6.i10.716]
71. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13: 631-647 [PMID: 19818310 doi: 10.1016/j.cld.2009.07.007]
72. Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535 [PMID: 19589948 doi: 10.1210/er.2009-0010]
73. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91-106 [PMID: 11310428 doi: 10.1079/pns200070]
74. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800 [PMID: 16799620 doi: 10.1038/sj.onc.1209556]
75. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997; 26: 598-604 [PMID: 9303488 doi: 10.1002/hep.510260310]
76. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001; 61: 5016-5023 [PMID: 11431335 doi: 10.1016/s0016-5085(08)80527-6]
77. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-678 [PMID: 12406438]
78. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62 [PMID: 12076862 doi: 10.1016/s0168-8278(02)00073-9]
79. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152 [PMID: 15254578 doi: 10.1172/JCI200422422]
80. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49: 1603-1616 [PMID: 20840865 doi: 10.1016/j.freeradbiomed.2010.09.006]
81. Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, Chung FL, Tang MS. The major lipid peroxidation product, trans-4-hydroxy-2- nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002; 23: 1781-1789 [PMID: 12419825 DOI: 10.1093/carcin/23.11.1781]
82. Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 2005; 102: 4120-4125 [PMID: 15738389 doi: 10.1073/pnas.0500660102]
83. Maeda S. NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis. Gastroenterol Res Pract 2010; 2010: 367694 [PMID: 21151655 doi: 10.1155/2010/367694]
84. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013; 14: 10497-10538 [PMID: 23698776 doi: 10.3390/ijms140510497]
85. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54 [PMID: 15239085]
86. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184 [PMID: 15239101 doi: 10.1002/hep.20282]
87. Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 2013; 35: 191-202 [PMID: 22945457 doi: 10.1007/s00281-012-0336-6]
88. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012; 1: 58-70 [PMID: 22724089]
89. Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Saji Y, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009; 39: 724-738 [PMID: 19473437 doi: 10.1111/j.1872-034X.2009.00509.x]
90. Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis 2011; 31: 128-146 [PMID: 21538280 doi: 10.1055/s-0031-1276643]
91. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013; 19: 5219-5238 [PMID: 23394097 doi: 10.2174/13816128113199990381]
92. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 doi: 10.1038/ng.257]
93. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520-528 [PMID: 18940312 DOI: 10.1016/j.ajhg.2008.09.012]
94. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217 [PMID: 20373368 DOI: 10.1002/hep.23622]
95. Burza MA, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, Svensson PA, Jacobson P, Adiels M, Baroni MG, Borén J, Ginanni Corradini S, Montalcini T, Sjöström L, Carlsson LM, Romeo S. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012; 44: 1037-1041 [PMID: 22704398 doi: 10.1016/j.dld.2012.05.006]
96. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61: 75-81 [PMID: 24607626 DOI: 10.1016/j.jhep.2014.02.030]